Details

NameSymbolSector
BIOCON LIMITEDBIOCONPharmaceuticals
Open
361
High
368
Low
358.15
Close
359.25
Volume
2525023
Exchange
nse
Time
14/08

Outlook

Score:  

3

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Biocon is  
High Wave
Estimated Stoploss of Biocon is ₹  
368
Biocon has a  
Bearishℹ
 pattern. 
Formation of  
High Wave
 candle pattern indicates the trend direction of Biocon is  
Unpredictableℹ
. 

Trend

Biocon is in  
Sideways trendℹ
. 
Price of Biocon is  
Downℹ
 by  

3.18

%. 
Target
Buy @ 

319.1

Sell @ 

405.98

Volume

The trade volumes of Biocon have become  
Deficientℹ
The volume trend for Biocon is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Biocon is  

Down

 by  

48.84

% 

Valuation

The current market price of Biocon is  
Overvaluedℹ

Financials

Balance
The balance sheet of Biocon is:  

Balanced

Cashflow
Biocon has  
Maintainedℹ
 cash flow because there is  

Surplus

 of  

₹ 2004cr

. It is  
Upℹ
 by  

627.37

%. 

(*Mar 2025)

65.71% i.e. ₹ 4061cr earned in operatingℹ
3.79% i.e. ₹ 234cr spent in investingℹ
30% i.e. ₹ 1854cr spent in financingℹ
0.5% i.e. ₹ 31cr earned in otherℹ
Biocon has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 380cr

. It is  
Downℹ
 by  

159.28

%. 

(*Mar 2024)

46.94% i.e. ₹ 2953cr earned in operatingℹ
15.96% i.e. ₹ 1004cr spent in investingℹ
37.07% i.e. ₹ 2332cr spent in financingℹ
0.03% i.e. ₹ 2cr earned in otherℹ
Income
The income of Biocon is  

₹ 4021cr

 and  

Profit

 is :  

₹ 89cr

(*Jun 2025)

Biocon Profit is down by:  

80.61

% and Income is Down by:  

9.7

% 

(*Jun 2025)

The income of Biocon is  

₹ 4453cr

 and  

Profit

 is :  

₹ 459cr

(*Mar 2025)

Biocon Profit is up by:  

466.67

% and Income is Up by:  

15.48

% 

(*Mar 2025)

The income of Biocon is  

₹ 3856cr

 and  

Profit

 is :  

₹ 81cr

(*Dec 2024)

Biocon Profit is up by:  

200

% and Income is Up by:  

6.46

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.